Daewoong Co., Ltd - 30 Oct 2026 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
10 Nov 2026, 11:35:47 UTC
Prior SEC filing
29 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Daewoong Co., Ltd., By: /s/ Bumseok Kim, Authorized Signatory
Filing notes and source

Key filing fact

Daewoong Co., Ltd filed Form 4 for AEON Biopharma, Inc. (AEON) on 10 Nov 2026.

Key facts

  • This page summarizes Daewoong Co., Ltd's Form 4 filing for AEON Biopharma, Inc. (AEON).
  • 3 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 10 Nov 2026, 11:35.

Change

  • Previous filing in this sequence was filed on 29 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001985493 Primary reporting owner

Daewoong Co., Ltd

Relationship
10%+ Owner
Address
244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, KOREA, REPUBLIC OF
Signature
Daewoong Co., Ltd., By: /s/ Bumseok Kim, Authorized Signatory
Signature date
10 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AEON transaction

Class A Common Stock, $0.0001 par value per share

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares
+11,236,631
Change %
+94%
Price
$0.000100*
Shares after
23,188,345
Date
30 Oct 2026
Ownership
By Daewoong Pharmaceutical Co., Ltd.
Footnotes
F1, F2
AEON transaction

Class A Common Stock, $0.0001 par value per share

Other

Transaction value
Shares
-3,822
Change %
-0.02%
Price
$0.2940*
Shares after
23,184,523
Date
30 Oct 2026
Ownership
By Daewoong Pharmaceutical Co., Ltd.
Footnotes
F1, F3
AEON holding

Class A Common Stock, $0.0001 par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
58,023
Date
30 Oct 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AEON transaction Derivative

Pre-Funded Warrant (right to buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares
-11,236,631
Change %
-100%
Price
$0.000000*
Shares after
0
Date
30 Oct 2026
Ownership
By Daewoong Pharmaceutical Co., Ltd.
Underlying class
Class A Common Stock
Underlying amount
11,236,631
Exercise price
$0.000100
Footnotes
F1, F2, F4
AEON holding Derivative

Common Stock Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,000,000
Date
30 Oct 2026
Ownership
By Daewoong Pharmaceutical Co., Ltd.
Underlying class
Class A Common Stock
Underlying amount
8,000,000
Exercise price
$1.09
Footnotes
F1, F5
AEON holding Derivative

Senior Secured Convertible Note

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
$1,500,000
Date
30 Oct 2026
Ownership
By Daewoong Pharmaceutical Co., Ltd.
Underlying class
Class A Common Stock
Underlying amount
Exercise price
Footnotes
F1, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F2

On October 30, 2026 (the "Exercise Date"), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise.

Footnote F3

Represents 3,822 shares of Class A Common Stock withheld by the Issuer in satisfaction of the aggregate exercise price of the Pre-Funded Warrants in accordance with the net exercise formula set forth in the Pre-Funded Warrant, based on the closing sale price of $0.294 per share on October 29, 2026, the trading day immediately preceding the Exercise Date. As a result of the cashless exercise, 11,232,809 shares of Class A Common Stock were issued to DWP.

Footnote F4

The Pre-Funded Warrants were exercisable at any time on or after January 21, 2026 and did not expire until exercised in full. Following the exercise described in footnotes (2) and (3), no Pre-Funded Warrants remain outstanding.

Footnote F5

The Common Stock Warrant has an exercise price of $1.09392 per share and is exercisable on or after the Initial Exercise Date and expires at 5:00 p.m. (New York City time) on the Termination Date, as such terms are defined in the form of warrant filed as Exhibit 4.2 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2025. The Common Stock Warrant may not be exercised to the extent that, after giving effect to such exercise, the holder together with its affiliates would beneficially own in excess of 49.99% of the Issuer's outstanding Class A Common Stock.

Footnote F6

The Senior Secured Convertible Note in the principal amount of $1,500,000 automatically converts, upon the completion by the Issuer of a bona fide third-party financing with aggregate gross cash proceeds of at least $30.0 million (a "Qualified Financing"), into a number of shares of Class A Common Stock (or pre-funded warrants in lieu thereof) equal to 1.3 multiplied by the quotient of (a) the principal amount and accrued but unpaid interest being converted divided by (b) the per share price in the Qualified Financing. The number of shares issuable upon conversion is therefore not determinable at this time.

SEC remarks

None.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .